In November 2004, the FDA issued a final rule requiring HCT/P establishments to operate in accordance with Current Good Tissue Practice (CGTP) for the collection, donor screening, donor testing, processing, storage, labeling, packaging and distribution of HCT/Ps to prevent the introduction, transmission and spread of communicable diseases. The core CGTP requirements cover facilities, environmental controls, equipment, supplies and reagents, recovery, processing and processing controls, labeling controls, storage, and distribution (including receipt and predistribution shipment). The regulations for CGTPs are found in 21 CFR 1271 Subpart D; FDA recommendations for compliance with the regulations also are available.
Cell Notes: What FDA’s Regulatory Flexibility Means for the Future of Cell and Gene Therapy
January 27, 2026
FDA Announces More Flexible Approach to CGT Regulation
January 13, 2026
REGULATORY UPDATE: FDA Releases 2026 CBER Guidance Agenda
January 12, 2026